SecBot SecBot
8-K ·Filed Jun 12, 2026

DNTH

Dianthus Therapeutics, Inc. /DE/
BULLISH
Impact 7/10
Horizonmonths Processed5mo ago SEC0001690585-26-000029
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The 75% CIDP responder rate and streamlined trial design significantly de-risk the CAPTIVATE program and support accelerated path to Part B top-line data by YE'26. With ~$1.2B cash runway into 2030 and multiple catalysts across gMG, CIDP, MMN, and DNTH212 over the next 6-18 months, the risk/reward is skewed positively. Monitor Ph. 3 gMG EMERGE initiation in mid-2026 and Ph. 2 MMN data in Q4'26 as the next key value inflection points.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$82.07
T+0 close · Jun 12, 2026 · via day close
Latest settled
+32.97%
T+60 · $109.13
Vs SPY
+29.71%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 12 $82.07entry
  2. T+1 · 5mo ago +0.54%α −1.23% · $82.51
  3. T+5 · 5mo ago +0.51%α −0.16% · $82.49
  4. T+20 · 4mo ago +18.92%α +17.14% · $97.60
  5. T+60 · 2mo ago +32.97%α +29.71% · $109.13
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dianthus Therapeutics posted an updated corporate presentation disclosing a 75% confirmed responder rate from the first 40 patients completing Part A of the Phase 3 CAPTIVATE trial of claseprubart in CIDP. The data supports an early GO decision and a streamlined trial design with ~1/3 fewer Part B patients, with Part B top-line guidance expected by YE'26. The filing also reiterates upcoming catalysts: Ph. 3 gMG EMERGE initiation (mid-'26), Ph. 2 MMN MoMeNtum data (Q4'26), and Ph. 1 DNTH212 data (2H'26).

Key Facts

  • 75% confirmed responder rate (30 of 40) in Part A of CAPTIVATE Ph. 3 CIDP trial, exceeding the 50% threshold for GO decision
  • CAPTIVATE trial design streamlined: Part B reduced from 192 to 128 patients, Part A enrollment capped at 256 vs. 480
  • No related serious infections, no clinical symptoms of DIL, no related SAEs or discontinuations in interim analysis
  • Cash position of ~$1.2B as of March 31, 2026, with runway into 2030
  • FDA Orphan Drug Designation received May 2026 for claseprubart in Myasthenia Gravis
  • Ph. 3 gMG EMERGE trial initiation expected mid-2026 with top-line data 2H'28
  • Ph. 2 MMN MoMeNtum top-line data expected Q4'26
  • Ph. 1 DNTH212 healthy volunteer top-line data expected 2H'26

Financial Impact

No financial figures reported in filing; cash position of ~$1.2B disclosed as of March 31, 2026

cash runwayclinical trial enrollmentpipeline value

Risk Factors

  • Interim analysis based on only 40 patients, final Part A and Part B results may differ
  • Ph. 3 gMG EMERGE top-line data not expected until 2H'28, a long wait for pivotal readout
  • Competitive landscape includes approved C5 inhibitors (Soliris, Ultomiris), FcRn blockers (Vyvgart), and emerging aC1s competitors (riliprubart, empasiprubart)
  • ANA positivity observed in 36.4% of 600mg/4mL arm in Ph. 2 gMG, though no clinical DIL symptoms reported
  • All pipeline candidates are investigational, no approved products or revenue

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001690585-26-000029
Document: dnth-20260612.htm0001690585-26-000029
Document: 0001690585-26-000029-index-headers.html0001690585-26-000029
Document: 0001690585-26-000029-index.html0001690585-26-000029
Document: 0001690585-26-000029.txt0001690585-26-000029

Track record

23 reports on DNTH

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +41.40% at T+60 after the Jun 11, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $89.76 Now $89.55 −0.23% settles Nov 17
  2. Nov 9, 20267d ago 144 Neutral 3/10 Entry $88.81 to $89.30 Now $89.55 +0.83% ▲ +0.55% −0.77% vs SPY
  3. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  4. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $83.01 to $86.03 Now $89.55 +7.88% ▲ +3.64% +3.33% vs SPY
  5. Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
  6. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
  7. Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $81.57 to $77.58 Now $89.55 +9.78% ▼ −4.89% −4.88% vs SPY
  8. Aug 11, 202613w ago Insider Cluster Neutral 4/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
  9. Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
  10. Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (9h 39m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 12, 2026